Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOMIRA RESEARCH (BIOM) -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (27)	12/28/1999 9:51:00 PM
From: chirodoc	Read Replies (1) \| Respond to of 72

PGNX vs. BIOM First I think comparisons such as this are not terribly meaningfull, but could be instructive of trading issues more than relative pipeline comparisons. To correct one notion, BIOM does not "have an HIV vaccine" in development. They were contracted to manufacture a vaccine candidate for another company, ID Biomedical. Biomira does have an interesting product that is highly applicable to HIV disease treatment, that is Liposomal IL-2 an immune modulator drug that is a "second generation IL-2" with an advanced delivery sustem that targets drug for slow release and greatly reduces the drugs toxicity levels (Chiron has IL-2 approved for melanoma, renal Ca and soon will get approval for HIV). Beyond this both Progenics and Biom have their primary franchise in cancer vaccines. The lead product from PGNX is a vaccine for melanoma (GMK vaccine) while Biom has Theratope in ph3 for Breast CA. There are follow on products for each of the leads, a breast CA vaccine for PGNX that is in early testing while BIOM has a vaccine for lung CA and breast in trials in BLP259 adding LipoIL-2 as combo in Jan 2000. So what is the big difference? Well for one BIOM is in Canada and PGNX is in NY. This does make a difference when cold hard cash is needed, as was shown in a very big financing by PGNX just completed. But Biom is still in very good shape cash wise and has a follow on 36million. What is the difference then, a partner. PGNX has a big gorilla of an oncology partner and Biom does not. I don't think either has a true lead in technology (both are sector leaders), in fact they are very similar vaccine concepts. So its NY NY and partners. Give BIOM a partner and the sky is the limit in 2000 REDPLATE